N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer

BACKGROUND

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival rate of less than 10%, owing to its late-stage diagnosis. Early detection of pancreatic cancer (PC) can significantly increase survival rates.

AIM

To identify the serum biomarker signatures associated with early-stage PDAC by serum N-glycan analysis.

METHODS

An extensive patient cohort was used to determine a biomarker signature, including patients with PDAC that was well-defined at an early stage (stages I and II). The biomarker signature was derived from a case-control study using a case-cohort design consisting of 29 patients with stage I, 22 with stage II, 4 with stage III, 16 with stage IV PDAC, and 88 controls. We used multiparametric analysis to identify early-stage PDAC N-glycan signatures and developed an N-glycan signature-based diagnosis model called the "Glyco-model".

RESULTS

The biomarker signature was created to discriminate samples derived from patients with PC from those of controls, with a receiver operating characteristic area under the curve of 0.86. In addition, the biomarker signature combined with cancer antigen 19-9 could discriminate patients with PDAC from controls, with a receiver operating characteristic area under the curve of 0.919. Glyco-model demonstrated favorable diagnostic performance in all stages of PC. The diagnostic sensitivity for stage I PDAC was 89.66%.

CONCLUSION

In a prospective validation study, this serum biomarker signature may offer a viable method for detecting early-stage PDAC.

High MEK/ERK signalling is a key regulator of diapause maintenance in the cotton bollworm, Helicoverpa armigera

MEK/ERK signalling has been identified as a key factor that terminates diapause in Sarcophaga crassipalpis and Bombyx mori. Paradoxically, high p-MEK/p-ERK signalling induces diapause in pupae of the moth Helicoverpa armigera; however, the regulatory mechanism is unknown. In the present study, we show that p-MEK and p-ERK are elevated in the brain of diapause-destined pupae and suppression of MEK/ERK activity terminates diapause progress. Reactive oxygen species (ROS) activate MEK/ERK signalling, causing large-scale phosphorylation of downstream proteins. The levels of ubiquitin-conjugated proteins are also significantly reduced when ROS or p-ERK level decreased. Moreover, terminated diapause progress by 20-hydroxyecdysone injection significantly decreases p-MEK, p-ERK and phospho-ribosomal S6 kinase levels, while phospho-MAPK substrates and ubiquitin-conjugated protein levels increase. Our data demonstrate that high MEK/ERK signalling mediated by ROS promotes diapause maintenance via increasing phosphorylation and degradation of downstream substrates. The results of this study may provide important information for understanding the regulatory mechanisms during insect diapause.

HRD1 attenuates the high uptake of [18F]FDG in hepatocellular carcinoma PET imaging

INTRODUCTION

Due to individual deviations in tumor tissue uptake, the role of [¹⁸F]fluorodeoxyglucose ([¹⁸F]FDG) positron emission tomography (PET) in hepatocellular carcinoma (HCC) diagnosis is limited. β-Hydroxy β-methylglutaryl-CoA reductase degradation 1 (HRD1) plays a key role in clearing misfolded proteins. This study is aimed to investigate the role and mechanism of HRD1 in [¹⁸F]FDG uptake for the diagnosis of HCC.

METHODS

HRD1 expression level was detected using immunohistochemical (IHC) staining in 9 HCC patients. [¹⁸F]FDG PET/CT scans were conducted before treatment. [¹⁸F]FDG uptakes in HRD1 overexpressed and knockdown transgenic models were measured by γ-counter and microPET imaging. The GLUT1-HRD1 complex was examined by co-immunoprecipitation and IHC assays. GLUT1 expression in different cell lines, xenograft models and HCC patients was evaluated by Western blot and IHC assays.

RESULTS

HRD1 was highly expressed in the HCC tumors of patients with low [¹⁸F]FDG uptake, while the HRD1 expression was obviously low in the higher [¹⁸F]FDG uptake group. Both in vitro and in vivo studies found that HRD1 significantly inhibited [¹⁸F]FDG uptake in HCC Huh7 cell lines and animal models. Furthermore, the co-location and interaction of HRD1 with GLUT1 were detected, and the results also indicate that HRD1 could induce the degradation of GLUT1 in vitro and in vivo.

CONCLUSION

HRD1 inhibits the high uptake of [¹⁸F]FDG in HCC tumor cells by inducing degradation of GLUT1, which leads to decreased diagnostic efficiency of [¹⁸F]FDG PET imaging for HCC.

ADVANCES IN KNOWLEDGE

This study suggests that HRD1 inhibits the high uptake of [¹⁸F]FDG in HCC tumor by inducing degradation of GLUT1.

IMPLICATIONS FOR PATIENT CARE

HCC diagnosis with [¹⁸F]FDG PET should be accompanied by determination of HRD1 expression, and patients with high tumor HRD1 expression might be unsuitable for [¹⁸F]FDG PET.

HRD1 sensitizes breast cancer cells to Tamoxifen by promoting S100A8 degradation

Estrogen receptor alpha positive (ER+) of breast cancer could develop resistance to antiestrogens including Tamoxifen. Our previous study showed that the E3 ubiquitin ligase HRD1 played an important role in anti-breast cancer. However, its role in chemotherapy resistance hasn't been reported. In this study, we found that HRD1 expression was downregulated in Tamoxifen-resistant breast cancer cell line MCF7/Tam compared to the Tamoxifen sensitive cell line MCF7. Moreover, S100A8 is the direct target of HRD1 by proteome analysis. Our data showed that HRD1 decreased the protein level of S100A8 through ubiquitination while HRD1 was regulated by acetylation of histone. More importantly, HRD1 knockdown significantly increased the cell survival of MCF7 cells to the Tamoxifen treatment. HRD1 overexpression sensitized MCF7/Tam cells to the Tamoxifen treatment in vitro and in vivo. In conclusion, the decrease of HRD1 expression contributed to Tamoxifen resistance in breast cancer.

mRNA expression of gonadotropin-releasing hormones (GnRHs) and GnRH receptor in goldfish

In goldfish (Carassius auratus), two distinct forms of gonadotropin-releasing hormone (GnRH), namely, salmon GnRH (sGnRH) and chicken GnRH-II (cGnRH-II), have been identified in the brain using chromatographic, immunological, and molecular cloning approaches. These two native GnRHs act on specific receptors in the anterior pituitary to stimulate the synthesis and release of gonadotropins and growth hormone in goldfish. To evaluate the potential roles of sGnRH and cGnRH-II in both neural and reproductive tissues in goldfish, we studied the mRNA expression of sGnRH, cGnRH-II, and GnRH receptor (GnRH-R) in discrete brain areas, pituitary, ovary, and testis by a combined reverse transcription-polymerase chain reaction (RT-PCR) and Southern blot analysis. Total RNA was extracted from various tissues of sexually recrudescent male and female goldfish and RT-PCR was performed with primers specific for GnRH-R complementary DNA (cDNA), sGnRH cDNA, cGnRH-II cDNA-1, and cDNA-2. Results showed that GnRHs and GnRH-R mRNAs are differentially distributed in the brain. In the goldfish brain, sGnRH mRNA was predominantly expressed in the forebrain areas (olfactory bulb, telencephalon, and hypothalamus) whereas cGnRH-II mRNA-1 were expressed in all brain areas including olfactory bulbs and optic tectum-thalamus. The expression level of cGnRH-II mRNA-2 was much lower than that of cGnRH-II mRNA-1 in the brain. On the other hand, GnRH-R mRNA was expressed in all brain regions and pituitary. In the ovary and testis, GnRH-R mRNA, sGnRH mRNA, and cGnRH-II mRNA-1, but not cGnRH-II mRNA-2, are expressed. Sequence analysis of the PCR products showed that nucleotide sequences of GnRH-R in gonads are identical with that in the brain and pituitary. The coexistence of GnRHs and GnRH-R mRNAs in both neural and gonadal tissues supports the notion that sGnRH and cGnRH-II may act as neurotransmitters and/or neuromodulators in the brain and as autocrine and/or paracrine hormones in gonadal tissues in addition to their established neuroendocrine roles at the pituitary of goldfish.

Evolution of neuroendocrine peptide systems: gonadotropin-releasing hormone and somatostatin

Nine vertebrate and two protochordate gonadotropin-releasing hormone (GnRH) decapeptides have been identified and sequenced. Multiple molecular forms of GnRH peptide were present in the brain of most species examined, and cGnRH-II generally coexists with one or more GnRH forms in all the major vertebrate groups. The presence of multiple GnRH forms has been further confirmed by the deduced GnRH peptide structure from cDNA and/or gene sequences in several teleost species and tree shrew. High conservation of the primary structure of GnRH decapeptides and the overall structure of GnRH genes and precursors suggests that they are derived from a common ancestor. Somatostatin (SRIF) is a phylogenetically ancient, multigene family of peptides. A tetradecapeptide, SRIF (SRIF14) has been conserved, with the same amino acid sequence, in representative species of all classes of vertebrate. Four molecular variants of SRIF14 have been identified. SRIF14 is processed from preprosomatostatin-I, which contains SRIF14 at its C-terminus; preprosomatostatin-I is also processed to SRIF28 in mammals and SRIF26 in bowfin. Teleost fish possess a second somatostatin precursor, preprosomatostatin-II, containing [Tyr7, Gly10]-SRIF14 at the C-terminus, that is mainly processed into large forms of SRIF.

Molecular cloning and expression of cDNA encoding brain preprocholecystokinin in goldfish

A cholecystokinin (CCK) precursor cDNA of 782 bp was identified from goldfish brain. The open reading frame (369 bp) encodes the 123 amino acid precursor which contains mono- and di-basic amino acid endoproteolytic cleavage, C-terminal alpha-amidation and tyrosyl sulfation sites. Expression studies revealed the presence of preproCCK mRNA in the gastrointestinal tract, pituitary and a wide range of brain areas from the olfactory bulbs to the posterior brain region. We have also confirmed the presence of CCK mRNA in the posterior ventrolateral hypothalamus by in situ hybridization, supporting a role of CCK in feeding behavior and regulation of pituitary hormone secretion.

Cloning and expression pattern of a second [His5Trp7Tyr8]gonadotropin-releasing hormone (chicken GnRH-H-II) mRNA in goldfish: evidence for two distinct genes

Complementary DNAs (cDNAs) encoding [Trp7Leu8]GnRH (sGnRH) and [His5Trp7Tyr8]GnRH (cGnRH-II) peptides have been isolated from the brain of goldfish (X. W. Lin and R. E. Peter, 1996, Gen. Comp. Endocrinol. 101, 282-296). In the present study we report the isolation of a second cDNA encoding cGnRH-II peptide in the brain of goldfish using reverse transcription (RT) and rapid amplification of cDNA ends. There is an overall 79.7% nucleotide sequence similarity between the two cGnRH-II cDNAs, with 65.3, 91.2, and 76.3% similarity between the 5'-untranslated regions, coding regions, and 3'-untranslated regions, respectively, of the two cGnRH-II cDNAs. Comparison of the two cGnRH-II precursors shows 87.2% amino acid similarity. The presence of two cGnRH-II genes was confirmed by the sequence analysis of the introns between exon II and exon III of the two cGnRH-II genes. Results indicate that the intron of the two cGnRH-II genes shows a high divergence in size and sequence, but contains the same splice junction. Expression of the two cGnRH-II mRNAs was detected by RT-polymerase chain reaction assay and Southern blot analysis in all five grossly dissected brain areas, olfactory bulbs and tracts, telencephalon, hypothalamus, optic tectum-thalamus, and posterior brain. However, there was a difference in apparent intensity of hybridization signal for the two cGnRH-II mRNAs in all brain areas, suggesting a difference of expression levels. sGnRH mRNA was detected in the olfactory bulbs, telencephalon, and hypothalamus, but not in midbrain and posterior brain areas. The present finding of duplicate cDNAs and genes for cGnRH-II in goldfish is in agreement with the recent tetraploidization in this species.

Goldfish gamma-preprotachykinin mRNA encodes the neuropeptides substance P, carassin, and neurokinin A

Two cDNAs, size 969 bp and 1146 bp respectively, encoding goldfish gamma-preprotachykinin (gamma-PPT) were identified. Both cDNAs contain the same 345 bp open reading frame. The deduced 114-amino acid gamma-PPT contains the sequence of substance P, carassin and neurokinin A. sequence analysis of the two cDNA 5'-untranslated regions shows that the two cDNAs may represent different PPT-A gene transcripts resulting from the alternative transcriptional start sites. Expression of gamma-PPT mRNA was detected in a wide range of brain areas from the olfactory bulbs to the posterior brain region, as well as in the intestine, testis and pituitary.

Expression of salmon gonadotropin-releasing hormone (GnRH) and chicken GnRH-II precursor messenger ribonucleic acids in the brain and ovary of goldfish

The complementary DNAs (cDNA) encoding the [Trp7Leu8]gonadotropin-releasing hormone (salmon GnRH; sGnRH) precursor and the [His5Trp7Tyr8]GnRH (chicken GnRH-II; cGnRH-II) precursor of the goldfish brain were isolated and sequenced using reverse transcription and rapid amplification of cDNA ends (RACE). The sGnRH precursor cDNA consists of 540 bp, including an open reading frame of 282 bp, and the cGnRH-II precursor cDNA consists of 682 bp, including an open reading frame of 258 bp. The 94 amino acid-long goldfish sGnRH precursor and 86 amino acid-long goldfish cGnRH-II precursor have the same molecular architecture as GnRH precursors identified to date in other vertebrate species. Using two sets of primers designed to be sense and antisense to the goldfish brain sGnRH precursor cDNA sequence, reverse transcription-polymerase chain reaction (RT-PCR) amplification of total RNA from brain and ovary at gonadal recrudescent, mature ( = prespawning), and postovulatory stages resulted in two predicted sizes of PCR products. The intensities of staining signals of ethidium bromide were similar between brain and ovary samples. The same RT-PCRs were carried out with two sets of primers for cGnRH-II precursor cDNA, resulting in two PCR products of predicted size; however, the ethidium bromide staining signals are much weaker for products amplified from ovarian cDNA than that from brain cDNA. Restriction enzyme analysis verified the expected RT-PCR products. Sequence analysis of ovarian sGnRH precursor cDNA generated by RACE of total RNA from recrudescent ovarian tissue revealed the identical sequence to that of the brain sGnRH cDNA. Northern blot analysis detected a single mRNA transcript of approximately 650 bases for the sGnRH precursor in both the brain and ovary, and 750 bases for the cGnRH-II precursor in the brain. These results demonstrate that two forms of GnRH precursor (sGnRH and cGnRH-II) mRNA are expressed in goldfish brain tissue and that the sGnRH transcript and a low level of cGnRH-II transcript are also expressed in the goldfish ovary.

Seasonal variations in gonadotropin responsiveness, self-priming, and desensitization to GnRH peptides in the common carp pituitary in vitro

Seasonal variations of the GtH release response to salmon GnRH (sGnRH) and [D-Arg6,Pro9NEt]-sGnRH (sGnRH-A) were investigated in female common carp at different stages of the reproductive cycle using perifused pituitary fragments. The responsiveness to sGnRH and sGnRH-A varied seasonally in common carp pituitaries in vitro, with the greatest GtH release response in pituitaries from sexually mature (preovulatory) fish compared to pituitaries from sexually regressed fish. The magnitude of this seasonal change in the GtH release response was greater for sGnRH-A than for sGnRH, and sGnRH-A has a higher potency than sGnRH, particularly in pituitaries from sexually mature fish. Desensitization of perifused pituitary fragments to sGnRH and sGnRH-A, and a self-priming effect of sGnRH-A on the GtH release response, caused by repeated pulse administrations of the GnRH peptides, varied with the stage of reproductive cycle of the common carp. Using pituitaries from sexually regressed female common carp, desensitization occurred only when a high dose of sGnRH or sGnRH-A was given as repeated pulses at short time intervals, and no self-priming was observed by repeated administrations of sGnRH and sGnRH-A. Using pituitaries from sexually mature female common carp, desensitization occurred when a high dose of sGnRH and both high and low dosages of sGnRH-A were given as repeated pulses at short time intervals. Self-priming, largely due to the increase in basal GtH levels, occurred in response to repeated pulses of low dosages of sGnRH-A given at long intervals.

The regulatory effects of thyrotropin-releasing hormone on growth hormone secretion from the pituitary of common carp in vitro

The effects of thyrotropin-releasing hormone (TRH) on growth hormone (GH) and gonadotropin (GtH) release, and the influences of somatostatin (SRIF), the dopamine agonist apomorphine (APO) and extracellular calcium on basal and TRH-induced GH release were examined using an in vitro perifusion system for pituitary fragments of common carp (Cyprinus carpio). Five minute pulses of different dosages of TRH stimulated a rapid and dose-dependent increase in GH release from the perifused pituitary fragments with an ED50 of 9.7 ± 2.3 nM. TRH was ineffective on GtH release. SRIF significantly inhibited basal and TRH-induced GH release from the perifused pituitary fragments, and the effects of SRIF were dose-dependent. APO induced a dose-dependent increase in basal and TRH-stimulated GH release from the perifused pituitary fragments. Increasing the concentrations of extracellular calcium from 0 mM to 1.25 mM resulted in an increase in basal and TRH-induced GH release. The high dose of calcium (6.25 mM) caused a slight decrease in basal and TRH-induced GH release compared with those at a concentration of 1.25 mM.

Growth hormone and gonadotropin secretion in the common carp (Cyprinus carpio L.): in vitro interactions of gonadotropin-releasing hormone, somatostatin, and the dopamine agonist apomorphine

The effects of salmon gonadotropin-releasing hormone (sGnRH) and the superactive agonist [D-Arg6, Pro9NEt]-sGnRH (sGnRH-A) on growth hormone (GH) and gonadotropin (GtH) release were examined using a perifusion system for pituitary fragments of the common carp (Cyprinus carpio). Perifusion of 2-min pulses of different concentrations of sGnRH or sGnRH-A stimulated a rapid and dose-dependent increase in GH release: ED50 values for sGnRH and sGnRH-A in stimulating GH release were 2.8 +/- 0.7 and 0.5 +/- 0.1 nM, respectively, indicating that the superactivity of sGnRH-A for stimulation of GtH release also applies in induction of GH release. Exposure of the pituitary fragments to 10 nM sGnRH or sGnRH-A alone resulted in increases in GH and GtH release on a similar temporal course. Apomorphine (10, 100, and 1000 nM) significantly inhibited basal and GnRH-induced GtH release in a dose-dependent manner and significantly stimulated basal GH release; however, APO did not enhance GnRH-induced GH release. Somatostatin (100 nM) significantly blocked basal release and 10 nM sGnRH- and sGnRH-A-induced GH release, but was ineffective on GtH release. Treatment with somatostatin (100 nM) in combination with apomorphine (100 nM) caused an increase in sGnRH-induced GH release compared to treatment with somatostatin alone; whereas, on GtH there was a significant decrease in basal and GnRH-induced levels, compared to treatment with somatostatin alone. These results indicate that GH release in common carp is regulated by somatostatin as GH release inhibitor. sGnRH and sGnRH-A act as GH-releasing factors; the mechanisms by which GnRH stimulates GH and GtH secretion are independent. The dopamine agonist apomorphine stimulates GH release and inhibits GtH release directly at the pituitary level.

[The effect of methylmercury on testicular function of mice]

The results showed that the amount of methylmercury (MeHg) in testis correlated positively with exposure doses (r = 0.99 P less than 0.01). MeHg affected the process of spermatogenesis, causing decrease of sperm count and increase of sperm abnormalities. Pathological and electron microscopic examinations indicated that spermatogenic cells were damaged by MeHg especially spermatogonium and spermatocyte. Changes of microstructure were mainly degeneration, fragmentation vacuolation and large lipid drop formation of spermatogenic cells. The acrosome of many spermatids showed obvious changes. Destruction of blood-testis barrier was observed in 1/10 LD50 group. Quantitative histological examination also confirmed that MeHg resulted in lessening of its area of seminiferous tubules and reduction of germ cells. The contents of testosterone were not decreased in the treated groups other than the 1/10 LD50 group.

[The transplacental effect of methylmercury on the chromosome of embryo liver cells in rat]

The effect of methylmercury on the chromosome of embryo liver cells of rat was studied in vivo. The results showed that the rate of chromosome aberration both of embryo liver cells and maternal bone marrow cells increased linearly with the dose of methylmercury. The linear equations were as follows: Yembryo liver cell = 10.30 + 2.54D (r = 0.9573, P less than 0.01) Ymarrow cell = 2.34 + 0.71D (r = 0.9782, P less than 0.01).

[A study of hazard of methylmercury pollution in no. 2 Songhua River to fishermen's health]

In the present paper the methyl mercury pollution in no. 2 Songhua river is reported. After ten years of continuous investigation, it was found that the health of fishermen who had eaten mercury polluted fish as a dietary for a long time was affected. There was an accumulation of methyl mercury in the fishermen's body and symptoms and pathologic changes related to toxication by methyl mercury. The average value of mercury content in fish (0.44-0.89 ppm) was shown to be above the maximum allowable concentration by one to three times. The intake of methyl mercury by the fishermen was in the range of 0.17-0.34 mg/per day and 90% of the mercury in the fishermen's body was from the polluted fish. The average mercury content in hair was 13-58 times higher than that of normal. The mercury concentration in urine after therapy was higher than that before by 10.6 to 33.3 times. There was a close correlation between mercury content in hair and in blood and the ratio was shown to be 250:1. The hazard of methyl mercury to fishermen was discussed.